

Closing Care Gaps

AI Innovation & Adoption in a Financially Sustainable Manner

Vibhor Gupta, PhD

Founder & CEO, Pangaea Data



Microsoft & NVIDIA Documentary
covering the Impact of Pangaea

Despite Billions in IT Spend, Millions of Patients Still Fall Through Care Gaps



COPD

~70%

of patients undiagnosed

\$2.4B

spent on treatment / year



CKD

3.96M

unaware they have CKD

+\$15K

higher cost per stage-4 patient



Mental health

63%

of adults with mental illness go
untreated

\$2.9B

annual spending on mental health
health



Oncology

53.3%

pancreatic cancer patients miss
GDMT

\$13.6B

cancer treatment spend / year



Variability in care

Rural, lower-income & lower-education patients face worse outcomes and greater barriers to treatment.

Insights Uncovered from Patient EHRs, Images & Genetic Data Help Close Care Gaps

Insights

Electronic Health Records
(notes, reports, summaries)




Earlier identification + GDMT saved:

- CKD: \$550K/yr (2,680 patients) ¹
- COPD: \$140K/yr +\$19K/yr from optimization (3,941 patients) ²

+

Medical Images



DR screening cost reduction over 45 months (1,793 patients):

- \$43.7K in eye services avoided ³



+

Genetic Screening

Next-generation sequencing saved (1M patients):

- Up to 2.1M for Medicare⁴
- ~\$250K for commercial payers

Repeatable, Transparent, Explainable: Pangaea's Platform Enables Proactive Care Gap Identification Without Requiring LLM Prompting



Pangaea's Technology

Multimodal Data Analysis

Genomic test results

Biomarker	Results
ESR1	Y537S mutation detected

Text Interpretation

Pt: Lauren Mercier, 64F

Metastatic ER-positive/HER2-negative breast adenocarcinoma with ongoing radiographic and clinical disease control
...

Temporal Analysis

July 2025

February 2026

Anastrozole Plus
Ribociclib Started

Stable Disease on First
Line Therapy

Guideline-based aggregation

Clinical Guidelines



2025 NCCN
Breast Cancer
Guidelines

✓ Metastatic HR-Positive
HER2-Negative Breast
Cancer

✓ Managed with first-line
endocrine therapy

✓ No BRCA testing found

Needs BRCA1/2 testing

Pangaea's platform selects the optimal method depending on the data analyzed

Pangaea's Platform Approach Outperformed Generic LLMs Across Disease Conditions For Accuracy, Usability & Value

✓ Conclusion

- Pangaea outperformed LLMs across disease conditions
- Pangaea rated highest for usability compared to 3 general-purpose LLMs

 Pangaea's Platform Accuracy

 Baseline LLM prompting (OpenAI GPT) Accuracy

 CKD	95%	90%
 COPD *	96%	78%
 Asthma *	97%	24%
 Diabetic Retinopathy **	94%	24%
 Uncontrolled Diabetes	100%	-
 Hypertension **	100%	98%
 mBC ***	100%	-

* At high risk of exacerbation; ** Requiring screening; *** Discordant second-line therapy

Maximizing the Value of Innovative Technology for Rural & Low- Resource Health Systems



Grants to Focus on Demonstrating Value in Improving Patient Outcomes & Then Scaling

Limitations

- Grants rarely focus on value driven outcomes
- Once funding ends, there is no path to scale & sustain care-gap closure

Solution

Reimbursement framework based on value creation



Health System in Texas

Clinical objectives:

- Find patients suitable for DR Screening
- Find COPD HRE patients
- Find at risk of CKD patients



Health System in North Dakota

Clinical objectives:

- Reduce proportion of patients with uncontrolled diabetes

When Care Gap Closure is Reimbursed on Value, Scale Becomes Self-Sustaining



Reimbursement
Framework Based on
Value of Closing Care
Gaps




Health systems can
extend work across
larger populations



Improve patient
outcomes



Improve financial
sustainability



Increase job
opportunities



Pangaea

Thank you

Imagine if AI could understand an individual's health based on their data

CONTACT

info@pangaeadata.ai

www.pangaeadata.ai